Skip to main content Back to Top
Advertisement

5/8/2018

Ezetimibe and Atorvastatin Tablets

Products Affected - Description

    • Liptruzet tablet, Merck, 10 mg/ 10 mg, unit of use packages of 90, NDC 66582-0320-54
    • Liptruzet tablet, Merck, 10 mg/ 10 mg, unit of use packages of 30, NDC 66582-0320-30
    • Liptruzet tablet, Merck, 10 mg/ 20 mg, unit of use packages of 90, NDC 66582-0321-54
    • Liptruzet tablet, Merck, 10 mg/ 20 mg, unit of use packages of 30, NDC 66582-0321-30
    • Liptruzet tablet, Merck, 10 mg/ 40 mg, unit of use packages of 90, NDC 66582-0322-54
    • Liptruzet tablet, Merck, 10 mg/ 40 mg, unit of use packages of 30, NDC 66582-0322-30
    • Liptruzet tablet, Merck, 10 mg/ 80 mg, unit of use packages of 90, NDC 66582-0323-54
    • Liptruzet tablet, Merck, 10 mg/ 80 mg, unit of use packages of 30, NDC 66582-0323-30

Reason for the Shortage

    • In January 2014, Merck recalled all Liptruzet lots from wholesalers due to packaging defects in the outer laminate foil pouches.
    • Merck discontinued Liptruzet in June 2016.

Available Products

    • No products are available.

Estimated Resupply Dates

    • Merck discontinued all Liptruzet presentations in June 2015.

Updated

Updated May 8, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 24, 2014 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins